FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 331:550 August 25, 1994 Number 8 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Belchetz, P. E. PubMed Citation

To the Editor: In his review of hormonal treatment of postmenopausal women (April 14 issue),¹ Dr. Belchetz states (in Table 4) that "Combination therapy is contraindicated in women with hyperlipidemia or established ischemic heart disease."

What is the basis for this surprising statement? Although there has been concern that the addition of a progestin to estrogen-replacement therapy may attenuate the beneficial effects of estrogen on the lipid profile, the results of two recent, large cross-sectional studies^2,3 suggest that the combination is associated with an equally favorable or more favorable profile of serum lipids and other risk factors, as compared with . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.